«The additional information we can now derive from tumor biomarkers such as E-cadherin, nm23 and microvessel counts should begin to allow us to tailor therapy according to individual tumor types,»
added Samuel Hellman, MD, A.N. Pritzker Distinguished Service Professor of
radiation and cellular
oncology at the University of Chicago and co-author of the paper.